Sou Hu Cai Jing·2025-08-02 15:49Core Insights - Genting Yong's strategic investment in I-Mab amounts to $30.9 million, equivalent to approximately HKD 242.6 million, making it the largest shareholder with a 16.1% stake [1] - This investment marks a significant step in Genting Yong's strategic positioning in the next-generation tumor immunotherapy sector [1] I-Mab's Core Technology and Pipeline Products - I-Mab is a global biotechnology company listed on NASDAQ under the ticker "IMAB," focusing on precision tumor immunotherapy [3] - The company has three clinical pipeline products: Givastomig (Claudin18.2x4-1BB bispecific antibody), Ragistomig (PD-L1x4-1BB bispecific antibody), and Uliledlimab (CD73 antibody) [3] - Recent clinical data from I-Mab indicates an objective response rate of 83% for Givastomig in a Phase 1b dose-escalation study for first-line gastric cancer treatment [3] Strategic Synergy and Global Layout Value - Genting Yong's CEO stated that the investment enhances the company's global strategy in next-generation tumor immunotherapy pipelines [4] - Genting Yong has developed proprietary AI+mRNA and autologous CAR-T platforms, focusing on mRNA therapeutic vaccines and autologous CAR-T therapies [4] - The collaboration between Genting Yong and I-Mab is expected to create a matrix of next-generation tumor immunotherapy products, providing innovative solutions for major treatment areas [4] - The investment leverages I-Mab's clinical development capabilities in the U.S. and complements Genting Yong's strong presence in the Asian market, potentially enhancing the value of core self-developed pipeline products in both the U.S. and China [4]